A Review Of Paniculoside I
All enrolled people who acquired at least one particular dose of zosuquidar or placebo for the duration of induction were being monitored with the prevalence of adverse events (439 individuals, 219 on zosuquidar and 210 on placebo). The commonest adverse activities have been connected with the duration of prolonged and major myelosuppression as is